Theranostics for COVID-19 Antiviral Drugs: Prospects and Challenges for Worldwide Precision/Personalized Medicine.
Caíque ManóchioSabrina Torres-LoureiroMariana M ScudelerBruno MiwaFernanda C Souza-SantosFernanda Rodrigues-SoaresPublished in: Omics : a journal of integrative biology (2023)
Coronavirus disease 2019 (COVID-19) is a systemic disease that impacts multiple organ systems with a complex clinical presentation and outcomes that can vary from person to person and between populations. To optimize COVID-19 treatment outcomes, and in light of the availability of antiviral drugs, there is a need for greater attention to the field of theranostics, the fusion of therapeutics and diagnostics. Theranostics tests would be invaluable, we suggest in this expert review, so as to optimize the efficacy and safety of current and future antiviral drugs against COVID-19. Theranostics would also assist in the design and implementation of clinical trials with antiviral drug candidates. We discuss here theranostics considering drugs such as remdesivir, Paxlovid™, and molnupiravir. All in all, we underscore that theranostics as a concept and practice is essential for efficient and safe health interventions against COVID-19 and other ecological crises in the 21st century.
Keyphrases
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- healthcare
- clinical trial
- primary care
- mental health
- risk assessment
- drug induced
- physical activity
- emergency department
- working memory
- climate change
- metabolic syndrome
- skeletal muscle
- small molecule
- adipose tissue
- human health
- open label
- double blind
- glycemic control
- health promotion